The 6th Imric Retreat

Irradiated CD19 chimeric antigen receptor YTS cells retain antitumor activity and offer a scalable alternative to autologous CAR T therapy.

Anas Abu Khalaf Hanan Jaber
Department of Immunology and Cancer Research, Hebrew University-Hadassah

Chimeric antigen receptor (CAR) is a synthetic receptor engineered into immune cells, empowering them to recognize and attack specific Target. CAR T cell therapies have revolutionized the treatment of hematologic malignancies, including lymphoma and multiple myeloma. However, their widespread clinical application remains limited by high manufacturing costs, dependence on autologous T cells, variable product quality, and potentially life-threatening toxicities such as cytokine release syndrome (CRS). In contrast, natural killer (NK) cells represent a safer and more flexible alternative. Nevertheless, the clinical translation of NK cell-based therapies is still hindered by complex expansion protocols, limited in vivo persistence, and high production costs. Here, we present a transformative approach using the human NK cell line YTS, which is amenable to large scale culture, genetic manipulation, and cryopreservation. By introducing a CD19-specific CAR into YTS cells, we generate potent effector cells capable of selectively eliminating CD19 expressing targets. We demonstrate that CAR signaling in YTS cells requires intracellular activation and, in certain tumor settings, is enhanced by co-stimulation via the 2B4-CD48 pathway. Importantly, irradiation of YTS-CAR cells prevents proliferation without compromising their cytotoxic function even after freezing and thawing. In preclinical models, injections of irradiated YTS-CAR cells significantly reduced CD19+ tumor burden, underscoring their therapeutic promise. This work positions engineered YTS cells as a novel, scalable, and cost-effective “off-the-shelf” immunotherapy platform suitable for treating refractory leukemias and lymphomas. Future studies will be required to assess safety and to explore applicability to autoimmune diseases and solid tumors.